The Global Gene-based Therapy Medicinal Market was valued at USD 9.06 Billion in 2023 and is projected to reach USD 72.55 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 26% during the forecast period (2023-2032). This remarkable growth stems from breakthroughs in viral vector technologies, increasing FDA approvals for gene therapies, and expanding applications across oncology, rare diseases, and neurological disorders.
As precision medicine redefines treatment paradigms, these biopharmaceutical leaders are advancing cutting-edge genetic solutions. This profile examines the Top 10 Companies in the Gene-based Therapy Medicinal Market—pioneers delivering transformative therapies through innovation pipeline development and strategic collaborations.
🔟 1. Biogen
Headquarters: Cambridge, Massachusetts, USA
Key Offering: Spinraza® (nusinersen) for Spinal Muscular Atrophy, neuro-focused gene editing platforms
Biogen maintains industry leadership with its FDA-approved SMA therapy Spinraza®, demonstrating 60% improvement in motor function. The company’s expanding neurological gene therapy portfolio includes partnerships with Sangamo Therapeutics for tauopathies and CRISPR-based Huntington’s disease treatments.
Clinical Pipeline:
- 6 ongoing Phase III trials for CNS disorders
- AAV9 vector delivery optimization programs
- Next-gen RNA-targeting Cas protein therapies
Download FREE Sample Report:
Gene-based Therapy Medicinal Market – View in Detailed Research Report
9️⃣ 2. Novartis
Headquarters: Basel, Switzerland
Key Offering: Zolgensma® (onasemnogene abeparvovec), Kymriah® CAR-T cell therapy
Novartis pioneered FDA-approved AAV9-based Zolgensma®, achieving 94% 5-year survival in SMA patients. Their Novartis Institutes for BioMedical Research drives advances in viral vector engineering and in vivo genome editing across 18 clinical programs.
Research Focus:
- Scalable AAV manufacturing technologies
- Cardiovascular gene therapies (CHF trial phase II)
- Neonatal screening integration for early intervention
8️⃣ 3. Gilead Sciences (Kite Pharma)
Headquarters: Foster City, California, USA
Key Offering: Yescarta®, Tecartus® CAR-T therapies for hematologic cancers
Gilead’s Kite Pharma division dominates the autologous CAR-T space with 58% market share in lymphoma treatments. Their lentiviral vector platform delivers durable responses in 70-90% of refractory large B-cell lymphoma cases.
Strategic Advancements:
- Point-of-care manufacturing network expansion
- Solid tumor T-cell engineering (Phase I/II trials)
- Allogenic cell therapy development platform
Read Full Report:
Gene-based Therapy Medicinal Market – Full Industry Analysis
7️⃣ 4. Sarepta Therapeutics
Headquarters: Cambridge, Massachusetts, USA
Key Offering: Elevidys® (delandistrogene moxeparvovec) for Duchenne MD
Sarepta leads the neuromuscular gene therapy sector with the first FDA-approved DMD treatment. Their RNA and gene therapy platforms address 80% of DMD mutations, with pipeline candidates targeting Limb-girdle MD and other rare disorders.
Technology Portfolio:
- Dual-vector gene editing systems
- Exon-skipping oligonucleotide platforms
- Microdystrophin construct optimization
6️⃣ 5. Alnylam Pharmaceuticals
Headquarters: Cambridge, Massachusetts, USA
Key Offering: RNAi therapeutics including Onpattro® and Amvuttra®
Alnylam’s RNA interference platform delivers gene silencing without DNA modification. Their 4 FDA-approved therapies treat hereditary ATTR amyloidosis and acute hepatic porphyria, with subcutaneous administration improving patient access.
Pipeline Highlights:
- 10 clinical-stage RNAi candidates
- CNS-targeted delivery systems in development
- Novel N-acetylgalactosamine conjugation methods
5️⃣ 6. Amgen
Headquarters: Thousand Oaks, California, USA
Key Offering: Oncology and cardiovascular gene therapies
Amgen integrates gene therapy across its biologics pipeline, advancing multiple oncolytic viruses and AAV-based cardiovascular treatments. Their recent acquisitions bring novel CRISPR and miRNA modulation capabilities.
Key Developments:
- Phase III LDL receptor gene therapy for HoFH
- T-VEC oncolytic virus combination trials
- Next-gen AAV production cell line development
Download FREE Sample Report:
Gene-based Therapy Medicinal Market – View in Detailed Research Report
4️⃣ 7. Spark Therapeutics (Roche)
Headquarters: Philadelphia, Pennsylvania, USA
Key Offering: Luxturna® (voretigene neparvovec) for retinal dystrophy
This Roche subsidiary pioneered FDA-approved ocular gene therapy, restoring vision in 93% of RPE65 mutation patients. Their proprietary AAV vector engineering enables targeted CNS and liver delivery with reduced immunogenicity.
Technical Advances:
- Blood-brain barrier crossing capsids
- Dosing optimization algorithms
- Closed-system manufacturing automation
3️⃣ 8. Akcea Therapeutics (Ionis)
Headquarters: Carlsbad, California, USA
Key Offering: Antisense oligonucleotide therapies
Akcea’s RNA-targeting platform modulates gene expression without viral vectors. Their treatments for hereditary TTR amyloidosis and familial chylomicronemia syndrome demonstrate 80-90% target protein reduction.
Platform Capabilities:
- Chemical modification for tissue specificity
- Subcutaneous delivery formulations
- Central nervous system delivery systems
2️⃣ 9. Orchard Therapeutics
Headquarters: London, United Kingdom
Key Offering: Ex-vivo hematopoietic stem cell gene therapies
Specializing in rare inherited disorders, Orchard’s Libmeldy® demonstrates 100% engraftment success in MLD patients. Their proprietary transduction enhancers improve lentiviral gene transfer efficiency to 85-95%.
Clinical Progress:
- Metachromatic leukodystrophy therapy commercialization
- Wiskott-Aldrich syndrome Phase III trials
- Automated cell processing systems
1️⃣ 10. Human Stem Cells Institute
Headquarters: Moscow, Russia
Key Offering: Neovasculgen® for peripheral artery disease
This emerging leader developed the first approved vascular gene therapy, demonstrating 78% amputation-free survival in critical limb ischemia. Their pipeline includes CAR-T and stem cell-gene therapy hybrids for oncology applications.
Innovation Areas:
- Non-viral plasmid delivery systems
- Angiogenic gene combinations
- Point-of-care gene therapy manufacturing
Read Full Report:
Gene-based Therapy Medicinal Market – Full Industry Analysis
🔬 Outlook: The Future of Gene Therapy is Precision and Accessibility
The gene therapy market is evolving from rare disease treatment to broader therapeutic applications, with manufacturing innovations reducing costs from millions to thousands per dose. Key developments are reshaping the treatment landscape:
📈 Critical Market Trends:
- Vector engineering breakthroughs enabling tissue-specific targeting
- Regulatory harmonization accelerating global approvals
- Closed-system automated manufacturing scale-up
- Payor models adapting to high-value one-time therapies
- Multi-gene editing platforms for complex disorders
These industry leaders continue advancing genetic medicine through cutting-edge science, strategic partnerships, and patient-centric delivery models that bring transformative treatments from bench to bedside.
Read Full Report:
Gene-based Therapy Medicinal Market – Comprehensive 2032 Forecast